On the public citation graph

Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer

https://doi.org/10.1007/s00262-019-02387-9
0 signed · 67 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cam4.1215openalex-snapshot
Metabolic characteristics of programmed cell death‐ligand 1‐expressing lung cancer on 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography
inferredcites →https://doi.org/10.1002/cam4.754openalex-snapshot
Higher preoperative serum levels of PD ‐L1 and B7‐H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF ‐targeted therapy and unfavorable prognosis of renal cell carcinoma
inferredcites →https://doi.org/10.1002/cncy.21987openalex-snapshot
Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations
inferredcites →https://doi.org/10.1002/ijc.29210openalex-snapshot
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
inferredcites →https://doi.org/10.1002/stem.2509openalex-snapshot
Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression
inferredcites →https://doi.org/10.1007/s00259-016-3425-2openalex-snapshot
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery
inferredcites →https://doi.org/10.1007/s00259-018-3988-1openalex-snapshot
Is it time to change our vision of tumor metabolism prior to immunotherapy?
inferredcites →https://doi.org/10.1007/s00428-016-1910-4openalex-snapshot
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
inferredcites →https://doi.org/10.1007/s00432-016-2184-6openalex-snapshot
Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer
inferredcites →https://doi.org/10.1007/s10238-018-0506-5openalex-snapshot
Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients
inferredcites →https://doi.org/10.1016/j.cllc.2018.02.008openalex-snapshot
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma
inferredcites →https://doi.org/10.1016/j.cllc.2018.04.014openalex-snapshot
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer
inferredcites →https://doi.org/10.1016/j.critrevonc.2018.06.007openalex-snapshot
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy
inferredcites →https://doi.org/10.1016/j.ejca.2016.03.002openalex-snapshot
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
inferredcites →https://doi.org/10.1016/j.ejca.2018.06.022openalex-snapshot
2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma
inferredcites →https://doi.org/10.1016/j.lungcan.2016.08.001openalex-snapshot
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib
inferredcites →https://doi.org/10.1016/j.lungcan.2016.11.023openalex-snapshot
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
inferredcites →https://doi.org/10.1016/j.lungcan.2018.03.001openalex-snapshot
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma
inferredcites →https://doi.org/10.1016/s0140-6736(16)00587-0openalex-snapshot
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
inferredcites →https://doi.org/10.1016/s0140-6736(16)32517-xopenalex-snapshot
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
inferredcites →https://doi.org/10.1038/cr.2008.80openalex-snapshot
A critical role of IFNγ in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1
inferredcites →https://doi.org/10.1038/leu.2014.137openalex-snapshot
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
inferredcites →https://doi.org/10.1056/nejmoa1501824openalex-snapshot
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1080/2162402x.2017.1310358openalex-snapshot
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
inferredcites →https://doi.org/10.1080/2162402x.2018.1452581openalex-snapshot
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab
inferredcites →https://doi.org/10.1097/jto.0000000000000551openalex-snapshot
Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy
inferredcites →https://doi.org/10.1097/md.0000000000006102openalex-snapshot
Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy
inferredcites →https://doi.org/10.1097/mnm.0000000000000832openalex-snapshot
Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer
inferredcites →https://doi.org/10.1158/1535-7163.mct-14-0983openalex-snapshot
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
inferredcites →https://doi.org/10.1158/2326-6066.cir-16-0329openalex-snapshot
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1182/blood-2005-07-2793openalex-snapshot
Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
inferredcites →https://doi.org/10.1186/s40425-016-0153-xopenalex-snapshot
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
inferredcites →https://doi.org/10.1186/s40425-018-0382-2openalex-snapshot
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
inferredcites →https://doi.org/10.1371/journal.pone.0045272openalex-snapshot
Mesenchymal Stem Cells Repress Th17 Molecular Program through the PD-1 Pathway
inferredcites →https://doi.org/10.18632/oncotarget.12810openalex-snapshot
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy
inferredcites →https://doi.org/10.18632/oncotarget.22025openalex-snapshot
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients
inferredcites →https://doi.org/10.18632/oncotarget.25949openalex-snapshot
Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
inferredcites →https://doi.org/10.18632/oncotarget.5682openalex-snapshot
Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
inferredcites →https://doi.org/10.21037/15200openalex-snapshot
Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer
inferredcites →https://doi.org/10.21037/21221openalex-snapshot
Non-small cell lung carcinoma: understanding cancer microenvironment to drive immunotherapy and patients’ selection
inferredcites →https://doi.org/10.21037/jtd.2018.04.99openalex-snapshot
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors
inferredcites →https://doi.org/10.21037/tcr.2017.06.42openalex-snapshot
Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer
inferredcites →https://doi.org/10.21037/tcr.2018.04.10openalex-snapshot
Non-small cell lung carcinoma: understanding cancer microenvironment to drive immunotherapy and patients’ selection
inferredcites →https://doi.org/10.2217/imt-2017-0187openalex-snapshot
Immunotherapy in Non-Small-Cell Lung Cancer: Potential Predictors of Response and New Strategies to Assess Activity
inferredcites →https://doi.org/10.3322/caac.21442openalex-snapshot
Cancer statistics, 2018
inferredcites →https://doi.org/10.3892/ol.2017.7105openalex-snapshot
Expression and clinical significance of programmed death‑1 on lymphocytes and programmed death ligand‑1 on monocytes in the peripheral blood of patients with cervical cancer
inferredcites →https://doi.org/10.3978/j.issn.1000-9604.2014.02.08openalex-snapshot
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← backgroundhttps://doi.org/10.5281/zenodo.3715959zenodo-depositor-declared
inferred← citeshttps://doi.org/10.1038/s41598-023-46405-4openalex-snapshot
Combination of tumor asphericity and an extracellular matrix-related prognostic gene signature in non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.1093/immadv/ltaf030openalex-snapshot
[89Zr]Zr-DFO-avelumab accumulation in resectable non-small cell lung carcinoma indicates a suppressive tumor microenvironment amendable to neoadjuvant avelumab treatment
inferred← citeshttps://doi.org/10.1177/03936155231192674openalex-snapshot
Diagnostic value of programmed cell death-ligand 1 expression on circulating tumor cells in lung cancer: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.2147/bctt.s331844openalex-snapshot
Challenges in Detection of Serum Oncoprotein: Relevance to Breast Cancer Diagnostics
inferred← citeshttps://doi.org/10.2967/jnumed.119.237768openalex-snapshot
Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18 F-FDG PET/CT
inferred← citeshttps://doi.org/10.3389/fendo.2022.913631openalex-snapshot
Negative Correlation Between 18F-RGD Uptake via PET and Tumoral PD-L1 Expression in Non-Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1754848openalex-snapshot
High PVR protein expression marks clear cell renal cell carcinoma with metastatic spread
inferred← citeshttps://doi.org/10.3389/fonc.2025.1578419openalex-snapshot
The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients
inferred← citeshttps://doi.org/10.3389/fphar.2022.1037341openalex-snapshot
Targeting glycolysis in non-small cell lung cancer: Promises and challenges
inferred← citeshttps://doi.org/10.3390/cancers12051163openalex-snapshot
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
inferred← citeshttps://doi.org/10.3390/cancers12061373openalex-snapshot
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
inferred← citeshttps://doi.org/10.3390/cancers13071634openalex-snapshot
Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience
inferred← citeshttps://doi.org/10.3390/ph15010075openalex-snapshot
Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse
inferred← citeshttps://doi.org/10.5281/zenodo.194816openalex-snapshot
Сучасні Вимоги До Професійної Діяльності Робітника Харчової Промисловості
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.